| 1 |
31058419 | Pharmacokinetic and haemodynamic interactions between amlodipine and losartan in human beings. | 2019 Oct |
1 |
| 2 |
27934636 | Impact of Probe Substrate Selection on Cytochrome P450 Reaction Phenotyping Using the Relative Activity Factor. | 2017 Feb |
1 |
| 3 |
26806573 | Effects of salvianolic acid B and tanshinone IIA on the pharmacokinetics of losartan in rats by regulating the activities and expression of CYP3A4 and CYP2C9. | 2016 Mar 2 |
1 |
| 4 |
27216792 | Drug Interactions with Angiotensin Receptor Blockers: Role of Human Cytochromes P450. | 2016 |
1 |
| 5 |
27474842 | Pharmacogenetic approach to losartan in Marfan patients: a starting point to improve dosing regimen? | 2016 Sep 1 |
1 |
| 6 |
25424246 | Drug-drug Interaction between Losartan and Paclitaxel in Human Liver Microsomes with Different CYP2C8 Genotypes. | 2015 Jun |
1 |
| 7 |
20716633 | Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study. | 2010 Sep |
1 |
| 8 |
11054425 | A kinetic model for the metabolic interaction of two substrates at the active site of cytochrome P450 3A4. | 2001 Jan 19 |
2 |
| 9 |
11408373 | Role of CYP2C9 polymorphism in losartan oxidation. | 2001 Jul |
1 |
| 10 |
10877007 | In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists. | 2000 May |
2 |
| 11 |
10197301 | The effects of fluvastatin, a CYP2C9 inhibitor, on losartan pharmacokinetics in healthy volunteers. | 1999 Apr |
2 |
| 12 |
9542475 | Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers. | 1998 Mar |
2 |
| 13 |
9551703 | Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174. | 1998 Feb |
1 |
| 14 |
7736913 | Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members. | 1995 Feb |
2 |